• board | Enterprise Therapeutics | Treatment of respiratory diseases

Board

Dr Peter Finan

Dr Peter Finan

Chairman

Dr Peter Finan is Partner at Epidarex Capital and currently serves on the board of Clyde Bioscienes, Caldan Therapeutics, Enterprise Therpeutics and Topas Therapeutics. More...

Dr John Ford

Dr John Ford

Chief Executive Officer

Dr John Ford has more than 18 years of ion channel, drug discovery and development experience. More...

Dr. Liz Roper

Dr. Liz Roper

Investor Director

Dr Liz Roper is Partner at Epidarex Capital Capital and currently serves on the board of Edinburgh Molecular Imaging, Caldan Therapeutics, Enterprise Therapeutics and Nodthera. More...

Dr David Morris MD

Dr David Morris MD

Investor Director

David is a Venture Partner at NVF in San Francisco, CA, USA. Prior to joining NVF, he held multiple leadership roles in the Novartis Pharmaceuticals development organization More...

Dr Alex Mayweg

Dr Alex Mayweg

Investor Director

Alex is a Partner at Versant. Alex is an accomplished leader in pharmaceutical drug discovery and medicinal chemistry across Europe, the U.S. and Asia. More...

Dr Gert-Jan Mulder MD

Dr Gert-Jan Mulder MD

Investor Director

Geert-Jan co-founded Forbion in 2006 and is currently the Managing Partner. Geert-Jan currently serves on several boards including AM-Pharma, Promedior Inc., Laboratoris Sanifit, NeRRe Therapeutics and KaNDy Therapeutics. More...

Dr Bobby Soni

Dr Bobby Soni

Investor Director

Bobby is currently Life Science Partner at IP Group plc. He joined Touchstone Innovations (now IP Group) in 2015 from Novo Seeds, the early stage investment arm of Novo AS where he worked as Investment Director.More...

Enterprise is a biopharmaceutical company dedicated to the research and development of novel therapies for the treatment of respiratory diseases of high unmet medical need and commercial opportunity – the company plans to initiate clinical trials in 2019.

Scientific Strategy

Enterprise is developing muco-regulatory drugs that are expected to help respiratory patients by improving their ability to breath and reduce the number of lung infections they experience leading to a longer and more healthy life.

Learn more

Pipeline

Enterprise has developed a pipeline of novel low molecular weight compounds with first in class potential – our most advanced compounds, which target ion channels in the airway epithelium are expected to enter human trials in late 2019.

Learn more